ResMed (NYSE: RMD) reported Q4 EPS of $0.68, $0.03 better than the analyst estimate of $0.65. Revenue for the quarter came in at $453.1 million versus the consensus estimate of $436.73 million.

For earnings history and earnings-related data on ResMed (RMD) click here.